Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 M91I |
| Therapy | Neratinib |
| Indication/Tumor Type | bladder carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 M91I | bladder carcinoma | sensitive | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of a bladder carcinoma cell line harboring ERBB3 (HER3) M91I in culture (PMID: 33473169). | 33473169 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33473169) | Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. | Full reference... |